“In a trial involving a small number of volunteers, the saRNA booster was given to people who'd already had two doses of the non-mRNA AstraZeneca vaccine. No serious side effects were found and a strong T cell response was triggered, which can help fight off any variants regardless of their spike protein mutations.”
“在一项涉及少数志愿者的试验中,saRNA 加强剂被给予已经接种过两剂非 mRNA 阿斯利康疫苗的人。没有发现严重的副作用,并触发了强烈的 T 细胞反应,这有助于抵御任何变异,无论它们的刺突蛋白突变如何。”
Novavax's two-dose, protein-based vaccine was authorized for use this week by European Union regulators and the World Health Organization. L1N2T50VX It has previously been approved by countries including Indonesia and the Philippines but not the United States.
The drugmaker will start shipping vaccines to the EU's 27 member states in January as part of its deal to supply up to 200 million doses.